Should I Buy PFE? PFE 2026 Analysis

Should You Buy Pfizer Inc (PFE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

26.100

1 Day change

0.93%

52 Week Range

27.690

Analysis Updated At

2026/01/26

Pfizer Inc. (PFE) is not a strong buy at this moment for a beginner investor with a long-term strategy. Despite some promising developments in weight management and cancer drug trials, the company faces significant challenges, including declining financial performance, revenue uncertainty, and upcoming patent expirations. The technical indicators are neutral, and the options data suggests a balanced sentiment. Analysts' ratings are mostly neutral, with no clear upward momentum in price targets. Therefore, it is advisable to hold off on investing in PFE until more favorable conditions emerge.

Technical Analysis

The technical indicators for PFE are mixed. The MACD is positive but contracting, RSI is neutral at 50.875, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 25.634, R1: 26.144, S1: 25.124. However, the stock's trend analysis indicates a high probability of a decline over the next week (-1.4%) and month (-32.69%).

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Late-stage trials for cancer drug PF-4404 and acquisition of MET-097i for weight management show potential for future growth.
Gross margin increased by 5.69% YoY in Q3 2025, indicating some operational efficiency improvements.

Neutral/Negative Catalysts

Significant revenue uncertainty due to upcoming patent expirations for key drugs like Eliquis.
Declining financial performance in Q3 2025, with revenue down 5.92% YoY, net income down 20.69% YoY, and EPS down 20.51% YoY.
Analysts have lowered price targets, citing challenges in offsetting revenue losses and faster-than-expected COVID-19 product erosion.

Financial Performance

Pfizer's Q3 2025 financials show a decline in revenue (-5.92% YoY), net income (-20.69% YoY), and EPS (-20.51% YoY). However, gross margin improved to 68.76%, up 5.69% YoY, indicating some operational efficiencies.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have a neutral stance on Pfizer. Recent ratings include Neutral from UBS with a $25 price target, and price target reductions from BofA and Morgan Stanley. Guggenheim and HSBC maintain a Buy rating but with modest price targets of $35 and $29, respectively. Analysts are concerned about revenue uncertainty and patent expirations, though some see potential in obesity drug developments.

16 Analyst Rating

Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 28.56 USD with a low forecast of 24 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

11 Hold

0 Sell

Moderate Buy

Current: 25.860

Low

Averages

28.56

High

Current: 25.860

Low

Averages

28.56

High

Cantor Fitzgerald

Neutral

maintain

$24 -> $27

AI Analysis

2026-01-27

New

Reason

Cantor Fitzgerald

Price Target

$24 -> $27

AI Analysis

2026-01-27

New

maintain

Neutral

Reason

Cantor Fitzgerald raised the firm's price target on Pfizer to $27 from $24 and keeps a Neutral rating on the shares. With 2026 guidance already issued and only modest beat-and-raise potential expected, the earnings call is likely to be quiet, with focus shifting to the timing and framing of VESPER-3 obesity data, the analyst tells investors in a research note Incremental updates on the Lyme disease vaccine, mevro in prostate cancer, or sigvotatug vedotin in non-small cell lung cancer are expected to be more influential than the 4Q25 results, the firm says.

UBS

Neutral

initiated

$25

2026-01-06

Reason

UBS

Price Target

$25

2026-01-06

initiated

Neutral

Reason

UBS assumed coverage of Pfizer with a Neutral rating and $25 price target. The firm noted a backdrop of continued revenue uncertainty with $15B-$20B in revenues from key drugs losing patient exclusivity over the coming roughly three years. Though the firm is positive on the recent MTSR obesity deal, Pfizer needs to do more to offset 2028 LOE risk, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PFE

Unlock Now

PFE Should I Buy

PFE Should I Buy

Should You Buy Pfizer Inc (PFE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch